Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 110, showing 5 Applications out of 550 total, starting on record 16, ending on 20

# ECCT Reference No Study Title Investigator(s) & Site(s)

16.

ECCT/25/07/01   FIH Study of CLY-124
    A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CLY-124 in Healthy Volunteers and Participants with Sickle Cell Disease   
Principal Investigator(s)
1. Bernhards Ogutu
Site(s) in Kenya
1. Strathmore University Medical Center [SUMC], Creates for Research in Therapeutic Sciences (Nairobi City county)
2. Victoria Biomedical Research Institute [VIBRI] (Kisumu county)
 
View

17.

ECCT/25/05/11   Sparkle study site-1406
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Doreen Mutua
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
View

18.

ECCT/25/06/03   ZHR-001
    Physiological and Biomarker Monitoring: Enhancing Vital Signs and Biomarkers Algorithm of Binah.AI in the Kenyan Population   
Principal Investigator(s)
1. Borna Achieng Nyaoke
Site(s) in Kenya
Zuri Health Medical Centre
 
View

19.

ECCT/25/05/07   Floral roll over study
    An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study.   
Principal Investigator(s)
1. Prof Jessie Githanga
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. KEMRI Kondele Children\'s Hospital (Kisumu county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
5. KEMRI WALTER REED KERICHO (Kericho county)
6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county)
7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county)
 
View

20.

ECCT/25/05/13   IVI CCV 002
    A Phase II, randomized, controlled, age-descending study in adults and children to evaluate the safety and immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in cholera-endemic region   
Principal Investigator(s)
1. Walter Jaoko
Site(s) in Kenya
KAVI - Institute of Clinical Research, University of Nairobi
 
View